Financial Performance - The company's revenue for Q3 2023 was ¥115,563,051.29, a decrease of 35.34% compared to the same period last year[5] - Net profit attributable to shareholders was ¥4,729,980.10, down 87.20% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,876,303.54, a decline of 80.92% compared to the previous year[5] - Total operating revenue for Q3 2023 was CNY 432,001,715.94, a decrease of 8.93% compared to CNY 474,349,508.65 in Q3 2022[21] - Net profit attributable to shareholders of the parent company for Q3 2023 was CNY 69,350,633.99, a decline of 26.31% from CNY 93,930,944.61 in Q3 2022[23] - Earnings per share for Q3 2023 was CNY 0.4790, compared to CNY 0.6487 in Q3 2022, reflecting a decrease of 26.14%[23] - The total comprehensive income for Q3 2023 was CNY 70,873,328.94, down from CNY 94,643,387.92 in Q3 2022, reflecting a decrease of 25.14%[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,084,644,058.91, an increase of 8.93% from the end of the previous year[5] - Total assets as of September 30, 2023, amount to CNY 2,084,644,058.91, an increase from CNY 1,913,773,127.42 at the beginning of the year[18] - Total liabilities as of the end of Q3 2023 amounted to CNY 599,832,973.01, an increase of 19.43% from CNY 502,254,330.46 at the end of Q3 2022[22] - Total current liabilities increased to CNY 289,164,333.34 from CNY 257,247,305.55[18] - The company’s non-current assets total CNY 1,102,088,376.60, up from CNY 1,014,457,091.93[18] Cash Flow - The company reported a significant decrease in cash flow from operating activities, with a net cash flow of ¥26,982,615.30, down 52.67% year-on-year[12] - The net cash flow from operating activities for Q3 2023 was ¥26,982,615.30, a decrease of 52.6% compared to ¥57,006,680.59 in Q3 2022[25] - Total cash inflow from investment activities was ¥252,244,395.95, significantly higher than ¥19,927,493.00 in the same period last year[25] - The net cash flow from financing activities was ¥118,695,921.78, compared to ¥132,412,177.85 in Q3 2022, reflecting a decrease of 10.5%[25] - The total cash outflow for operating activities was ¥372,607,381.03, down from ¥404,133,194.40 in Q3 2022[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,850[13] - Liu Zhongliang holds 60.89% of shares, totaling 88,160,400 shares[13] - The number of shares held by the top ten shareholders represents a significant concentration of ownership, with the top shareholder alone holding over 60%[13] - Liu Zhongliang and Liu Zhongjiao, who are siblings, are the primary shareholders, indicating potential family influence in company decisions[13] Inventory and Borrowings - The company’s inventory increased by 36.83% to ¥158,871,664.81, attributed to increased stocking by subsidiaries[9] - Long-term borrowings rose by 273.10% to ¥124,589,474.13, mainly due to increased bank loans for the pharmaceutical health industry park project[9] Research and Development - Research and development expenses for Q3 2023 were CNY 19,866,229.36, a decrease of 29.38% compared to CNY 28,067,342.97 in Q3 2022[22] Investment Income - The company experienced a 245.71% increase in investment income, amounting to ¥7,203,488.32, primarily due to confirmed income from financing trade business[10] - The company reported an investment income of CNY 7,203,488.32 for Q3 2023, significantly higher than CNY 2,083,670.00 in the same period last year[22]

浙江维康药业股份有限公司 第三届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300878 证券简称：维康药业 公告编号：2023-037 一、监事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）于 2023 年 10 月 20 日以 电子邮件、专人送达或电话方式发出第三届监事会第十三次会议通知，会议于 2023 年 10 月 27 日在浙江省丽水经济开发区遂松路 2 号研发大楼会议室以现场 方式召开，应参加表决的监事 3 人，实际参加表决的监事 3 人，会议由公司监事 会主席叶萍主持。本次会议的召集、召开和表决程序符合有关法律、法规、部门 规章、规范性文件和《公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2023 年第三季度报告的议案》 经审核，监事会认为：董事会编制和审议公司 2023 年第三季度报告的程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日 ...

证券代码：300878 证券简称：维康药业 公告编号：2023-036 浙江维康药业股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）第三届董事会第十四次会 议通知于 2023 年 10 月 20 日以电子邮件、专人送达或电话方式送达全体董事， 本次会议于 2023 年 10 月 27 日在浙江省丽水经济开发区遂松路 2 号研发大楼会 议室以现场结合通讯方式召开。本次会议由董事长刘忠良先生主持，公司应出席 董事 7 人，实际出席董事 7 人。本次董事会会议的召集、召开和表决程序符合有 关法律、法规、部门规章、规范性文件和《公司章程》的规定，决议内容合法有 效。 二、董事会会议审议情况 2023 年 10 月 27 日 1、审议通过《关于公司 2023 年第三季度报告的议案》 经审议，董事会认为：公司《2023 年第三季度报告》的编制程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际 情况，不存在任何虚假记载、误导 ...

证券代码：300878 证券简称：维康药业 公告编号：2023-035 浙江维康药业股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押的基本情况 浙江维康药业股份有限公司（以下简称"公司"）近日接到公司控股股东、实 际控制人刘忠良先生的通知，获悉其所持有本公司的部分股份办理了质押业务，具 体情况如下： | | 是否为控 | | | | 是否为限 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押 | 占其所持 | 占公司 | 售股（如 | 为补 | 质押 | 质押到 | | 质押 | | 名称 | 第一大股 | 数量 | 股份比例 | 总股本 | 是，注明 | 充质 | 起始 | 期日 | 质权人 | 用途 | | | 东及其一 | （股） | | 比例 | 限售类 | 押 | 日 | | | | | | 致行动人 | | | | 型） | ...

民生证券股份有限公司 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意浙江维康药业股份有限公司首次公开 发行股票注册的批复》（证监许可〔2020〕1652 号）同意注册，公司向社会公众 公开发行人民币普通股（A 股）20,110,000 股，并于 2020 年 8 月 24 日在深圳证 券交易所创业板上市。首次公开发行后公司总股本为 80,439,068 股，其中有限售 条件股份数量为 60,329,068 股，占公司总股本的 75.00%；无限售条件的股份数 量为 20,110,000 股，占公司总股本的 25.00%。 （二）上市后股本变动情况 2022 年 6 月 17 日，公司实施了 2021 年度权益分派方案，以公司总股本 80,439,068 股为基数，以资本公积金向全体股东每 10 股转增 8 股。本次权益分 派实施完成后，公司总股本由 80,439,068 股增加至 144,790,322 股。 关于浙江维康药业股份有限公司首次公开发行部分限售股 解禁上市流通的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为浙江 维康药业 ...

证券代码：300878 证券简称：维康药业 公告编号：2023-034 浙江维康药业股份有限公司 首次公开发行前已发行股份上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、浙江维康药业股份有限公司（以下简称"公司"）本次解除限售的股份数 量为 103,853,745 股，占公司总股本的 71.73%。本次实际可上市流通数量为 27,937,870 股，占公司股本总额的比例为 19.30%。 2、本次解除限售股份上市流通日期为 2023 年 9 月 19 日（星期二）。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意浙江维康药业股份有限公司首次公开发 行股票注册的批复》（证监许可〔2020〕1652 号）同意注册，公司向社会公众公开 发行人民币普通股（A 股）20,110,000 股，并于 2020 年 8 月 24 日在深圳证券交易所 创业板上市。首次公开发行后公司总股本为 80,439,068 股，其中有限售条件股份数 量为 60,329,068 股，占公司总股本的 75.0 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥316.44 million, representing a 7.04% increase compared to ¥295.62 million in the same period last year[18]. - Net profit attributable to shareholders was approximately ¥64.62 million, reflecting a 13.40% increase from ¥56.99 million year-on-year[18]. - The net profit after deducting non-recurring gains and losses was approximately ¥57.23 million, which is a 30.49% increase compared to ¥43.86 million in the previous year[18]. - The net cash flow from operating activities reached approximately ¥47.93 million, a significant increase of 70.68% from ¥28.08 million in the same period last year[18]. - Basic earnings per share were ¥0.4463, up 13.39% from ¥0.3936 in the same period last year[18]. - Total assets at the end of the reporting period were approximately ¥2.03 billion, an increase of 5.89% from ¥1.91 billion at the end of the previous year[18]. - Net assets attributable to shareholders were approximately ¥1.46 billion, reflecting a 4.62% increase from ¥1.40 billion at the end of the previous year[18]. - The company's total comprehensive income for the first half of 2023 was CNY 65,525,522.35, compared to CNY 57,521,230.39 in the same period of 2022, reflecting a growth of 14.0%[146]. Investment and R&D - The company has established multiple research and development platforms, including provincial high-tech enterprise research centers and Nobel Prize workstations, enhancing its core competitiveness in the pharmaceutical field[30]. - The company emphasizes R&D investment and talent introduction, continuously developing new drugs in areas such as antibiotics and gynecology[30]. - The company is currently conducting clinical trials for its product "Yinhuang Diyan" for recurrent oral ulcers, which is in phase IIb trials[39]. - The company has completed the material standard research for "Jinshui Liujun Decoction" and is progressing with the formulation research according to national guidelines[39]. - The company has a new product "Kaixin San" under research, aimed at treating insufficient heart qi, with ongoing formulation studies[39]. - The company has committed to invest 72,559 million CNY in the pharmaceutical health industry park project, which includes traditional Chinese medicine and extraction centers[68]. Market and Industry Context - The company operates in the pharmaceutical manufacturing industry, specifically in the "27 Pharmaceutical Manufacturing" sector, benefiting from national policy support and increasing health awareness among the population[26]. - The Chinese pharmaceutical market is experiencing growth due to factors like aging population and increased health consciousness, with significant government support for traditional Chinese medicine[26]. - In 2023, the National Medical Products Administration introduced measures to strengthen the regulation of traditional Chinese medicine, indicating a favorable policy environment for the industry[27]. - The government has outlined a comprehensive plan to promote the revitalization and development of traditional Chinese medicine, which is expected to further boost the industry[28]. Quality Control and Compliance - The company emphasizes quality control throughout the production process, ensuring compliance with GMP standards and conducting thorough inspections of raw materials and finished products[35]. - The company adheres to high quality standards, with all products meeting or exceeding the national standards set by the Pharmacopoeia of the People's Republic of China (2020 edition)[45]. - The company has implemented a comprehensive quality management system covering all operational aspects, from R&D to sales[45]. - The company actively fulfills its social responsibilities, ensuring the protection of shareholder interests and maintaining a good working environment for employees[90]. Risk Management - The company has identified potential risk factors in its operations, which are detailed in the report[3]. - The company faces significant policy risks due to the highly regulated nature of the pharmaceutical industry, which requires timely adjustments to changes in national healthcare policies[76]. - The company is increasing its R&D investment and talent acquisition to reduce innovation risks associated with the lengthy and complex drug development process[78]. - Management risks are anticipated due to rapid expansion; the company plans to enhance training for existing management personnel and recruit new managers to address these challenges[79]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 12,055[123]. - The largest shareholder, Liu Zhongliang, holds 60.89% of the shares, totaling 88,162,900 shares[123]. - Liu Zhongliang's sister, Liu Zhongjiao, holds 6.82% of the shares, totaling 9,872,000 shares[123]. - The company has not distributed cash dividends or issued bonus shares for the half-year period, nor has it increased capital through reserves[85]. Financial Position - The company's total assets reached ¥2,026,497,930.10, compared to ¥1,913,773,127.42 at the start of the year, showing a growth of about 5.9%[138]. - Total liabilities amounted to ¥550,034,650.79 as of June 30, 2023, compared to ¥502,254,330.46 at the beginning of the year, marking an increase of about 9.5%[138]. - The company's retained earnings grew to ¥576,393,007.30 from ¥511,772,353.41, reflecting an increase of approximately 12.6%[138]. - The company has 124 drug operation licenses, with 2 new licenses added and 11 licenses canceled during the reporting period[50]. Corporate Governance - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[71][72][73]. - The half-year financial report has not been audited[99]. - The company has not reported any changes in the shareholding of directors, supervisors, and senior management during the reporting period[125].

一、监事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日以电 子邮件、专人送达或电话方式发出第三届监事会第十二次会议通知，会议于 2023 年 8 月 28 日在浙江省丽水经济开发区遂松路 2 号研发大楼二楼会议室以现场方 式召开，应参加表决的监事 3 人，实际参加表决的监事 3 人，会议由公司监事会 主席叶萍主持。本次会议的召集、召开和表决程序符合有关法律、法规、部门规 章、规范性文件和《公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审核公司 2023 年半年度报告全文及摘要 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 证券代码：300878 证券简称：维康药业 公告编号：2023-029 浙江维康药业股份有限公司 第三届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特此公告 ...

浙江维康药业股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 2023半年度 法定代表人： 主管会计工作的负责人： 会计机构负责人： 编制单位：浙江维康药业股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2022年期初 | 2022年度占用累 计发生金额 | 2022年度占用 资金的利息 | 2022年度偿还 | 2022年期末 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 占用资金余额 | （不含利息） | （如有） | 累计发生金额 | 占用资金余额 | | | | 控股股东、实际控制人及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | | | | | | | | | | | | 前控股股东、实际控制人及其 | | | | | | | | | | 非经营性占用 ...

证券代码：300878 证券简称：维康药业 公告编号：2023-033 浙江维康药业股份有限公司 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经中国证券监督管理委员会《关于同意浙江维康药业股份有限公司首次公开发 行股票注册的批复》（证监许可〔2020〕1652号）同意注册，公司向社会公开发行 人民币普通股（A股）2,011万股，本次公开发行人民币普通股每股面值为人民币 1.00元，发行价格为41.34元/股，本次发行募集资金总额为83,134.74万元，扣除发行 费用后募集资金净额为72,559.56万元。上述募集资金到位情况已经天健会计师事务 所（特殊普通合伙）进行了验证，并于2020年8月19日出具了"天健验〔2020〕323 号"《验资报告》。公司对募集资金采取了专户存储制度，设立了相关募集资金专 项账户。募集资金到账后，已全部存放于募集资金专项账户内，并与保荐机构、存 放募集资金的银行签署了募集资金三方监管协议。 二、募集资金使用情况 截至 2023 年 6 月 30 日，本次募集资金使用情况如下： 单位：万元 ...